









Markets
/
Stocks
/
nasdaq-mist
/

Milestone Pharmaceuticals Inc

MIST

1.840USD

-0.010-0.54%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

98.43MMarket Cap

LossP/E TTM



Milestone Pharmaceuticals Inc

1.840

-0.010-0.54%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Milestone Pharmaceuticals Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Milestone Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

147 / 407

Overall Ranking

271 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.500

Target Price

+89.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Milestone Pharmaceuticals Inc Highlights

StrengthsRisks

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Fairly Valued

The company’s latest PE is -2.20, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 19.30M shares, decreasing 22.65% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.24.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.70, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.70

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.70

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Milestone Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.48, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -2.20, which is -65.04% below the recent high of -0.77 and -64.23% above the recent low of -3.61.

Score

Industry at a Glance

Previous score

6.48

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 147/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 7.20, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Milestone Pharmaceuticals Inc is 4.00, with a high of 5.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.500

Target Price

+89.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Milestone Pharmaceuticals Inc

MIST

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.07, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 2.07 and the support level at 1.69, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.21

Change

-0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.032

Sell

RSI(14)

42.771

Neutral

STOCH(KDJ)(9,3,3)

38.736

Neutral

ATR(14)

0.098

Low Volatility

CCI(14)

-97.057

Neutral

Williams %R

74.992

Sell

TRIX(12,20)

-0.266

Sell

StochRSI(14)

17.529

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.866

Sell

MA10

1.875

Sell

MA20

1.943

Sell

MA50

1.927

Sell

MA100

1.816

Buy

MA200

1.705

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 22.71%, representing a quarter-over-quarter increase of 20.42%. The largest institutional shareholder is Steven Cohen, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Trails Edge Capital Partners LP

5.33M

Simplify Asset Management Inc

990.00K

+16.47%

Oliveto (Joseph Gerard)

2.51M

+2.73%

RTW Investments L.P.

2.51M

Propel Bio Management, LLC

1.79M

+23.42%

Alta Fundamental Advisers LLC

1.40M

-2.00%

BML Capital Management LLC

1.14M

Morgan Stanley & Co. LLC

817.82K

-15.33%

TD Securities, Inc.

750.00K

Lion Point Capital, L.P.

548.81K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 4.71, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.